NYSE:OGEN
Oragenics Inc Stock News
$1.40
-0.0100 (-0.709%)
At Close: Mar 27, 2024
Oragenics Announces Early Top-Line Results of Phase 2 Clinical Trial of AG013 for Oral Mucositis in Chemoradiation Treatment of Head and Neck Cancer
The Week Ahead In Biotech: Spotlight On Q1 Pre-Announcements As COVID-19 Continues To Disrupt Operations
06:03pm, Sunday, 05'th Apr 2020
Biotech stocks went along with the broader market flow in the week ended April 3, with the COVID-19 pandemic dictating sentiment. The week witnessed a host of clinical readouts...
Analysts Are Bullish on Top Healthcare Stocks: Cassiopea SpA (CPPSF), Oragenics (OGEN)
11:16am, Tuesday, 31'st Mar 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cassiopea SpA (CPPSF), Oragenics (OGEN) and CytomX
OGEN: Results from Phase 2 Trial of AG013 in Early 2Q20…
02:50pm, Monday, 09'th Mar 2020
By David Bautz, PhD NYSE:OGEN READ THE FULL OGEN RESEARCH REPORT Business Update Topline Data for Phase 2 Trial of AGO13 in Oral Mucositis in Early 2Q20 Oragenics, Inc. (NYSE:OGEN) is currently conduc
We're Keeping An Eye On Oragenics's (NYSEMKT:OGEN) Cash Burn Rate
04:16pm, Tuesday, 10'th Dec 2019
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Oragenics Inc. to Present at the LD Micro 12th Annual Main Event on December 10, 2019
01:30pm, Tuesday, 03'rd Dec 2019
Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced that Alan Joslyn, Ph.D.,
OGEN: AG013 Phase 2 Trial Enrollment Complete…
02:45pm, Monday, 02'nd Dec 2019
By David Bautz, PhD NYSE:OGEN READ THE FULL OGEN RESEARCH REPORT Business Update Enrollment Complete for Phase 2 Trial of AGO13 in Oral Mucositis Oragenics, Inc. (NYSE:OGEN) is currently conducting a
Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral Mucositis
01:30pm, Monday, 02'nd Dec 2019
Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced the completion of en
Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces the publicatio
Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announces the company’s Senior Vi